Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report highlights the importance of considering frontal fibrosing alopecia in young women, emphasizing early diagnosis to preserve hair and limit inflammation.

This study generated a transcriptomic map of human hair follicles, identifying compartment-specific gene expression profiles that can aid in developing targeted therapies for hair follicle disorders.

This study identified significant genetic associations with frontal fibrosing alopecia at four genomic loci, suggesting it is a genetically predisposed immuno-inflammatory disorder influenced by the HLA-B*07: 02 allele.

This study reported high patient satisfaction with multidisciplinary shared medical appointments for alopecia areata and frontal fibrosing alopecia, with participants appreciating the educational and supportive group environment.

This study found that hyaluronic acid increased the size of hair follicle germ-like aggregates and the number of proliferative cells but did not maintain specific markers during the process.

This research developed new in vitro models for high-throughput screening of drugs that could protect or restore immune privilege in hair follicles, finding that Tofacitinib was effective in preventing inflammation-related marker upregulation, while Tacrolimus and αMSH worked specifically in outer root sheath keratinocytes.

This review found that hair antiretroviral concentration may be associated with several factors, including hair type and genetic factors, but not with race/ethnicity or alcohol use.

This article discusses the formation and membership of the British Association of Hair Restoration Surgeons and reports no clinical findings.

This study found that adding allergen immunotherapy to conventional treatment may reduce relapse-related hair loss in house dust mite-allergic alopecia areata patients over a 3-year period.

In this study, sensitization to ethylhexyl salicylate was found in 27.3% of patients with frontal fibrosing alopecia, suggesting it may be a potential contact allergen for this condition.

This article explains the relevance of the American Medical Association to ISHRS members for health policy and medical education, with no new research findings reported.

This article reviews the causes and current treatment options for androgenetic alopecia, reporting no new clinical findings and highlighting the need for more therapeutic choices.

This review reported that 5-alpha-reductase inhibitors were effective in stabilizing disease progression or reducing the rate of progression in some cases of frontal fibrosing alopecia, though evidence on safety remains limited.

This study found that a novel method of isolating human follicle stem cells from hair follicles via mechanical centrifugation, without culture conditions, promises to improve hair density in patients with Androgenetic Alopecia and some cases of Alopecia Areata.

This case report describes a unique presentation of frontal fibrosing alopecia characterized by a hair loss pattern that resembles the Greek letter upsilon, supported by trichoscopic and histological findings.

This letter reports on a case of intractable ophiasis-type alopecia areata that was presumably improved by fexofenadine, but no new clinical results are presented.

This study found that patients with alopecia areata had significantly higher serum MIF levels compared to healthy controls, which correlated with greater disease severity and duration.

This study found that lifestyle factors such as diet, personal history, and psychological stress may be linked to the development of adult female acne, based on observed associations in a case-control setting.

This study found that despite challenges, a combination of oral antibiotics, anti-androgens, oral retinoids, biologics, and surgery were important in managing hidradenitis suppurativa in patients with intellectual and developmental disabilities.

This study suggests the existence of a new subtype of alopecia, called 'acute diffuse and total alopecia of the female scalp (ADTAFS)', characterized by acute, diffuse hair loss primarily in women and a rapid recovery.

The researchers reported that treating Alopecia Areata patients with the homeopathic remedy Fluoric Acid resulted in substantial hair regrowth and reduced relapse rates over a 6-year period, suggesting it may be an effective alternative to conventional treatments.

This study found a severe MBTPS2 gene mutation in a Japanese IFAP syndrome patient, suggesting other factors may influence the syndrome's clinical features compared to previously studied patients.

In this study, patients with specific skin and scalp conditions, including eczematous lesions, showed significant improvement after two weeks of oral tofacitinib treatment, as evidenced by changes in the trunk lesions.

This study investigated a unique frontal fibrosing alopecia-like presentation of alopecia areata, finding that patients experienced an insidious, chronic course with limited scalp hair regrowth, and showed a lower response to systemic corticosteroids compared to patchy alopecia areata.

HDMHG0401-10 improves hair loss in men with androgenetic alopecia and has no major side effects.

This review discusses the potential usefulness and safety profile of oral antiandrogens for treating frontal fibrosing alopecia, noting possible benefits but acknowledges that finasteride's efficacy remains uncertain.

This study observed that the coexistence of Frontal Fibrosing Alopecia and lupus erythematosus in a patient may suggest a shared pathogenic background.

In this case report, a 3-year-old male with IFAP syndrome showed moderate improvement in skin symptoms and corneal erosions but no change in alopecia or photophobia after 6 months of acitretin therapy.

HGF activator helps convert HGF to its active form, promoting hair growth.